| No | Age | Sex | Site of IPMN | MD (mm) | BDs (mm) | IDT (mm) | Follow-up period | Detection of DC | Site of DC | Confirmation of DC | Size of DC | Stage of DC | Resectability of DC | Treatment for DC§ |
| 1 | 73 | M | body | 3/3 (8) | 23/28 | 0/0 | 45 months | CT | Head | PJC | 25 mm | IVA | Resectable | CRT |
| 2 | 78 | F | tail | 3/3 | 35/35 | 0/0 | 18 months | CT | Head | US-FNA | 40 mm | IVA | Unresectable | CRT |
| 3 | 80 | F | head | 8/12 | 20/40 | 5/0 | 42 months | US | Body | PJC | 20 mm | III | Resectable | ND |
| 4 | 72 | F | head | 3/3 | 20/20 | 0/5 | 28 months | US | Body | EUS-FNA | 12 mm | III | Resectable | Resection |
| 5 | 69 | M | head | 3/3 (5) | 10/12 | 0/0 | 112 months | MRCP | Tail | PJC | 14 mm | III | Resectable | Resection |
BDs, branch ducts, at the initial/latest examination; CRT, chemoradiotherapy; DC, ductal carcinoma; FNA, fine needle aspiration, resectable; IDT, intraductal tumour, at the initial/latest examination; IPMN, intraductal papillary mucinous neoplasm; MD, main duct, at the initial/latest examination (upstream dilatation); ND, not done; PJC, pancreatic juice cytology.